A publication involving thymosin alpha-1 was released on July 1, 2026. The paper is titled "Regarding IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression." It appears in the Journal of Gastroenterology and Hepatology.
This entry is listed as a publication event and reflects the availability of the article, not a summary of its findings. Thymosin alpha-1 is currently classified as unapproved for research use, and this publication does not change that regulatory status. No dosing, efficacy, or safety conclusions are reported here beyond the fact that the article has been published under the stated title.
Readers interested in the specific data, methods, or conclusions presented in this paper should consult the original source directly through the provided link. As with all peptide research, publication of a paper does not by itself indicate regulatory approval or clinical use. For more background on thymosin alpha-1, see the compound overview linked with this brief.